SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-024539
Filing Date
2022-11-10
Accepted
2022-11-10 16:35:43
Documents
62
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q virx-20220930.htm   iXBRL 10-Q 3477324
2 EX-10.1 virx-ex10_1.htm EX-10.1 98312
3 EX-31.1 virx-ex31_1.htm EX-31.1 13921
4 EX-31.2 virx-ex31_2.htm EX-31.2 13920
5 EX-32.1 virx-ex32_1.htm EX-32.1 6445
6 EX-32.2 virx-ex32_2.htm EX-32.2 6379
  Complete submission text file 0000950170-22-024539.txt   10723342

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT virx-20220930_cal.xml EX-101.CAL 40686
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT virx-20220930_lab.xml EX-101.LAB 499254
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT virx-20220930_def.xml EX-101.DEF 263984
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT virx-20220930.xsd EX-101.SCH 60045
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT virx-20220930_pre.xml EX-101.PRE 377635
56 EXTRACTED XBRL INSTANCE DOCUMENT virx-20220930_htm.xml XML 1907099
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51531 | Film No.: 221377905
SIC: 2834 Pharmaceutical Preparations